Cargando…

Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects

This open‐label, single‐dose, randomized, parallel‐group, 2‐arm phase 1 bioequivalence (BE) study assessed the pharmacokinetics (PK), safety, and tolerability of PF‐06410293 (ADL‐PF), an adalimumab (ADL) biosimilar, following administration by prefilled pen (PFP) or prefilled syringe (PFS). A total...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Donna S., Alvarez, Daniel F., Bock, Amy E., Cronenberger, Carol L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518774/
https://www.ncbi.nlm.nih.gov/pubmed/33765358
http://dx.doi.org/10.1002/cpdd.939
_version_ 1784584302673002496
author Cox, Donna S.
Alvarez, Daniel F.
Bock, Amy E.
Cronenberger, Carol L.
author_facet Cox, Donna S.
Alvarez, Daniel F.
Bock, Amy E.
Cronenberger, Carol L.
author_sort Cox, Donna S.
collection PubMed
description This open‐label, single‐dose, randomized, parallel‐group, 2‐arm phase 1 bioequivalence (BE) study assessed the pharmacokinetics (PK), safety, and tolerability of PF‐06410293 (ADL‐PF), an adalimumab (ADL) biosimilar, following administration by prefilled pen (PFP) or prefilled syringe (PFS). A total of 164 healthy adult subjects were randomized (1:1) to receive ADL‐PF (40 mg subcutaneously) in the lower abdomen or upper anterior thigh by PFS or PFP; 163 subjects were included in the primary PK analysis. The concentration‐time profiles of the ADL‐PF PFS and PFP treatment arms were similar. The 90% confidence intervals for the test/reference ratios of the primary end points (area under the serum concentration‐time profile from time 0 to 2 weeks after dosing and maximum observed serum concentration) fell within the 80.00%‐125.00% prespecified margin for BE. Comparable numbers of subjects experienced adverse events (AEs) between treatment groups, and injection‐site pain was similar at all times and for the 2 injection‐site locations. This study demonstrated the BE of ADL‐PF following subcutaneous administration using either a PFS or PFP device. ADL‐PF by PFS or PFP injection was well tolerated, with the distribution of AEs, including injection‐site reactions, being similar between treatment arms.
format Online
Article
Text
id pubmed-8518774
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85187742021-10-21 Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects Cox, Donna S. Alvarez, Daniel F. Bock, Amy E. Cronenberger, Carol L. Clin Pharmacol Drug Dev Articles This open‐label, single‐dose, randomized, parallel‐group, 2‐arm phase 1 bioequivalence (BE) study assessed the pharmacokinetics (PK), safety, and tolerability of PF‐06410293 (ADL‐PF), an adalimumab (ADL) biosimilar, following administration by prefilled pen (PFP) or prefilled syringe (PFS). A total of 164 healthy adult subjects were randomized (1:1) to receive ADL‐PF (40 mg subcutaneously) in the lower abdomen or upper anterior thigh by PFS or PFP; 163 subjects were included in the primary PK analysis. The concentration‐time profiles of the ADL‐PF PFS and PFP treatment arms were similar. The 90% confidence intervals for the test/reference ratios of the primary end points (area under the serum concentration‐time profile from time 0 to 2 weeks after dosing and maximum observed serum concentration) fell within the 80.00%‐125.00% prespecified margin for BE. Comparable numbers of subjects experienced adverse events (AEs) between treatment groups, and injection‐site pain was similar at all times and for the 2 injection‐site locations. This study demonstrated the BE of ADL‐PF following subcutaneous administration using either a PFS or PFP device. ADL‐PF by PFS or PFP injection was well tolerated, with the distribution of AEs, including injection‐site reactions, being similar between treatment arms. John Wiley and Sons Inc. 2021-03-25 2021-10 /pmc/articles/PMC8518774/ /pubmed/33765358 http://dx.doi.org/10.1002/cpdd.939 Text en © 2021 Pfizer Inc. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Cox, Donna S.
Alvarez, Daniel F.
Bock, Amy E.
Cronenberger, Carol L.
Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects
title Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects
title_full Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects
title_fullStr Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects
title_full_unstemmed Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects
title_short Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects
title_sort randomized, open‐label, single‐dose, parallel‐group pharmacokinetic study of pf‐06410293 (adalimumab‐afzb), an adalimumab biosimilar, by subcutaneous dosing using a prefilled syringe or a prefilled pen in healthy subjects
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518774/
https://www.ncbi.nlm.nih.gov/pubmed/33765358
http://dx.doi.org/10.1002/cpdd.939
work_keys_str_mv AT coxdonnas randomizedopenlabelsingledoseparallelgrouppharmacokineticstudyofpf06410293adalimumabafzbanadalimumabbiosimilarbysubcutaneousdosingusingaprefilledsyringeoraprefilledpeninhealthysubjects
AT alvarezdanielf randomizedopenlabelsingledoseparallelgrouppharmacokineticstudyofpf06410293adalimumabafzbanadalimumabbiosimilarbysubcutaneousdosingusingaprefilledsyringeoraprefilledpeninhealthysubjects
AT bockamye randomizedopenlabelsingledoseparallelgrouppharmacokineticstudyofpf06410293adalimumabafzbanadalimumabbiosimilarbysubcutaneousdosingusingaprefilledsyringeoraprefilledpeninhealthysubjects
AT cronenbergercaroll randomizedopenlabelsingledoseparallelgrouppharmacokineticstudyofpf06410293adalimumabafzbanadalimumabbiosimilarbysubcutaneousdosingusingaprefilledsyringeoraprefilledpeninhealthysubjects